• The risk of cerebral venous thrombosis (CVT) in patients with cancer is not known.
Summary. Background: Cancer is an established risk factor for leg vein thrombosis and pulmonary embolism. Controlled studies assessing the risk of cerebral venous thrombosis (CVT) in patients with cancer have not been performed. Objective: To assess whether cancer is a risk factor for CVT. Patients/Methods: This was a case-control study. We assessed consecutive adult patients with CVT from three academic hospitals from 1987 to 2015, and control subjects from the Dutch MEGA study (Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis). We adjusted for age, sex and oral contraceptive use, and stratified for type of cancer and time since diagnosis of cancer. Results: We included 594 cases and 6278 controls. In total, 53 cases (8.9%) and 160 controls (2.5%) had a history of cancer. Cases were younger (median 42 vs. 48 years), more often female (68% vs. 54%) and more often used oral contraceptives (55% vs. 23%) than controls. The risk of CVT was increased in patients with cancer compared with those without cancer (adjusted odds ratio [aOR], 4.86; 95% confidence interval [CI], 3.46-6.81). Patients with a hematological type of cancer had a higher risk of CVT (aOR, 25.14; 95% CI, 11.64-54.30) than those with a solid type of cancer (aOR, 3.07; 95% CI, 2.03-4.65). The association was strongest in the first year after diagnosis of cancer (hematological aOR, 85.57; 95% CI, 19.70-371.69; solid aOR, 10.50; 95% CI, 5.40-20.42). Conclusions: Our study indicates that cancer is a strong risk factor for CVT, particularly within the first year of diagnosis and in patients with a hematological type of cancer.
Introduction
Cancer is an established risk factor for common locations of venous thromboembolism (VTE), such as deep vein thrombosis of the leg and pulmonary embolism. Data from previous studies indicate that the risk of VTE is increased approximately 4-to 7-fold in patients with cancer [1] [2] [3] [4] . The risk is higher early after diagnosis of cancer [1, 5, 6] . Different factors contribute to the elevated risk, including changes in hemostasis, enhanced expression of procoagulant factors by tumor cells, and treatment with chemotherapeutic and hormonal agents [3, 7, 8] .
Cerebral venous thrombosis (CVT) is a rare form of VTE that mainly affects young and middle-aged adults [9] . Risk factors for CVT partly overlap with those for leg vein thrombosis and pulmonary embolism, including genetic thrombophilia and oral contraceptive use. However, other risk factors, such as head trauma and ear infections, are specific for CVT [10, 11] . Cancer is generally also believed to be a risk factor for CVT, but controlled studies assessing the association between CVT and cancer have never been performed [12] [13] [14] . Data from cohort studies suggest that around 7% of patients with CVT have a history of cancer at the time of CVT diagnosis [15, 16] .
The aim of our study was to determine (i) if cancer is a risk factor for CVT, (ii) if the magnitude of the risk differs between various types of cancer, and (iii) whether there is a time relation between cancer diagnosis and the risk of CVT.
Methods

Study design and patient selection
We performed a case-control study. Cases were patients derived from three hospital-based CVT registries: the Academic Medical Center (Amsterdam, the Netherlands), Helsinki University Central Hospital (Helsinki, Finland) and Sahlgrenska University Hospital (Gothenburg, Sweden). In these hospitals, data on consecutive adult patients with CVT have been collected since January 2000 (Amsterdam), January 1987 (Helsinki) and January 1997 (Gothenburg). In the Helsinki and Amsterdam registries, data have been collected prospectively since 2010 and 2006, respectively. We included patients diagnosed up to 1 January 2016. Diagnosis of CVT was confirmed in all patients with computed tomographic-venography, MRI with MR-venography, catheter angiography or autopsy, in accordance with international guidelines [14] .
Controls were subjects who participated in the control arm of the Dutch Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) study [1] . This case-control study included 4956 consecutive patients aged 18 to 70 years with a first deep vein thrombosis of the leg or arm, or pulmonary embolism, between March 1999 and September 2004. Partners of patients and subjects identified by random digit dialing were asked to participate as control subjects. In total, 6297 controls (3297 partners and 3000 by random digit dialing) were included. Participants in the control group were between the ages of 18 and 70 years and could not have a history of venous thrombosis. Additional details of the study have been reported previously [1] . We excluded cases and controls for whom it was unknown if they had a history of cancer.
The MEGA study was approved by the Ethics Committee of the Leiden University Medical Center, Leiden, the Netherlands, and written informed consent was obtained from all subjects. Because only observational data were collected for patients with CVT, written informed consent was not required under applicable national legislation.
Data collection and definition of cancer
For cases, baseline characteristics, risk factors for thrombosis, imaging findings and clinical outcome were recorded using a standardized case record form. Each control subject completed a questionnaire on acquired risk factors for thrombosis, which included detailed information on history of cancer. Date of diagnosis, type of cancer and details of treatment were recorded for all subjects. To verify self-reported data, discharge letters from control subjects with cancer were collected from their primary physician, or from the hospital in which they had been treated. Non-invasive skin cancer (e.g. basal cell carcinoma), meningioma, myelodysplastic syndrome and malignancies diagnosed more than 10 years before the index date without signs of active disease, were not registered as cancer. We subdivided cancer into hematological (leukemia, lymphoma and myeloma) and solid malignancies.
Statistical analysis
Odds ratios (ORs) with 95% confidence intervals (CI) were calculated as an approximation of relative risks, which indicates the risk of CVT in the presence of cancer relative to in the absence of cancer. We applied standard multivariate logistic regression analysis with CVT as a dependent variable, adjusting for age (as a continuous variable), sex and oral contraceptive use. In subgroup analyses, we stratified for type of cancer (hematological vs. solid), time of diagnosis (< 1 year, 1-3 years and 3-10 years) and type of hematological cancer (leukemia vs. other forms of hematological cancer). We performed a sensitivity analysis excluding cases who were diagnosed with cancer concomitantly with CVT. To address the possibility of a bias as a result of possible differences in background incidence of cancer between the three countries, we performed a sensitivity analysis including only cases from the Amsterdam cohort. All data were analyzed with IBM SPSS Statistics version 22 (New York, NY, USA).
Results
There were 595 cases (n = 224 Amsterdam cohort, n = 243 Helsinki cohort, n = 128 Gothenburg cohort) and 6297 controls within the specified time period. We excluded one case and 19 controls because it was not recorded whether they had a history of cancer. Therefore, the study population consisted of 594 cases and 6278 controls. Cases were younger (median 42 vs. 48 years), more often female (67% vs. 54%) and more often used oral contraceptives (55% vs. 23%). The baseline characteristics of cases and controls are provided in Table 1 .
In total, 53 cases (8.9%) and 160 controls (2.5%) had a history of cancer (Table 2) . Twenty-three out of 53 cases had a hematological type of cancer. Eighteen of these were leukemia: 16 acute lymphoblastic leukemia (ALL), one acute myeloid leukemia and one chronic lymphoblastic leukemia (CLL). Other types of hematological cancer were lymphoma (n = 3) and multiple myeloma (n = 2). Of the 16 cases with ALL, 15 were being treated with Lasparaginase and/or intrathecal methotrexate at the time of CVT. Ten out of 160 controls with cancer had a hematological malignancy, of whom three had leukemia: one had CLL and in the two others the type of leukemia was not specified. Six controls had a history of lymphoma and one had multiple myeloma. Two of the 53 cases were diagnosed with cancer concomitantly when they were diagnosed with CVT. In both cases, routine ancillary investigations led to the diagnosis of cancer.
Thirty cases had a history of solid cancer, most commonly breast cancer (n = 8), gastrointestinal cancer (n = 5) and lung cancer (n = 4). Of the 150 controls with a history of solid cancer, breast cancer was reported in 47 subjects, followed by gynecologic cancer in 17 subjects and gastrointestinal cancer in 15 subjects. Distant metastases were present in 11 cases (1.9%) and 21 controls (0.3%).
After adjustment for age, sex and oral contraceptive use, the risk of CVT was increased in patients with cancer (adjusted odds ratio [aOR], 4.86; 95% CI, 3.46-6.81; Table 2 ). The risk was clearly higher in patients with hematological cancer (aOR, 25.14; 95% CI, 11.64-54.30), but still increased 3-fold in patients with a solid type of cancer (aOR, 3.07; 95% CI, 2.03-4.65). Patients with leukemia had the highest risk of CVT (aOR, 51.20; 95% CI, 14.76-177.59). When subjects with leukemia were excluded from the analysis, hematological malignancies were still associated with CVT (aOR, After the first year of cancer diagnosis there was no clear association between cancer and CVT. Sensitivity analysis excluding the two cases that were diagnosed with cancer concomitantly with CVT showed a similar risk of CVT compared with the main analysis (aOR, 4.68; 95% CI, 3.33-6.58). Sensitivity analysis using only cases from the Amsterdam cohort demonstrated a similar risk of CVT in patients with cancer to that when we included all cases (aOR, 4.34; 95% CI, 2.50-7.51).
Discussion
Our data show that a history of cancer increases the risk of CVT approximately 5-fold. The risk was markedly higher in patients with hematological types of cancer compared with those with a solid malignancy. Patients were especially at risk of developing CVT the first year after diagnosis of a hematological malignancy; these patients had an almost 90 times higher risk of developing CVT than subjects without cancer.
An inverse relation between the risk of thrombosis and the time since diagnosis of cancer has been observed for more common locations of VTE. This probably relates to the fact that prothrombotic changes initiated by cancer cells occur more frequently in the early stages of the disease [1, 17] . Surgery and chemotherapy, which add to the risk of thrombosis, are generally also performed early after diagnosis [1, 5, 17] .
Previous case series and cohort studies have suggested that patients with ALL are prone to develop CVT [18, 19] . The exact mechanisms of this association are unclear, but the use of L-asparaginase and intrathecal methotrexate during induction therapy is thought to be the culprit [18] [19] [20] . Our case-control study confirms the association of CVT with ALL and provides an estimate of the strength of this association. Overall, 2.7% of patients with CVT had a history of ALL, compared with only three controls (0.05%) with leukemia. Of these, one had CLL and for the other two control subjects, the type of leukemia was not recorded. The over-representation of patients with ALL is probably the reason why we observed that the risk of CVT is skewed towards hematological types of cancer. This observation is in contrast to more common forms of VTE, where the risk increase is more or less similar for hematological and solid types of cancer [1] . Nevertheless, the increased risk of CVT in hematological types of cancer was not fully attributable to ALL. When we excluded subjects with leukemia, hematological cancer still increased the risk of CVT approximately 10-fold. Our study has several limitations that warrant comment. First, we included CVT cases from three European countries, whereas the control group consisted only of Dutch residents. As a result, a variation in the background incidence of cancer between countries could have biased the results. Data from the World Health Organization, however, do not indicate a significant difference in incidence of cancer between Sweden, Finland and the Netherlands [21] . Moreover, we performed a sensitivity analysis including only CVT cases from the Amsterdam cohort, and the point estimate in this analysis was similar to that of the main analysis. Second, subjects with cancer may theoretically have been reluctant to participate as a control in the MEGA study, which could lead to an overestimation of the association between CVT and cancer. This issue, which was also a concern in the original MEGA study [1] , was tackled by contacting subjects who refused to participate as a control to determine if they had a history of cancer. Of the 459 subjects who refused to participate as a control, only one had a history of cancer. There was no difference in the incidence of cancer between the general population in the Netherlands and control subjects during recruitment years, or in subjects identified by RDD and partners of patients in the MEGA study [22] . Therefore, we feel that it is unlikely that a selection bias in the control population affected the results. Third, we considered the risk of diagnostic suspicion bias, which would occur when cancer is diagnosed in the cases as a result of the routine ancillary investigations. However, sensitivity analysis excluding the two out of 53 cases that were diagnosed with cancer concomitantly with CVT showed similar results to the main analysis. A final limitation of our study is that it was underpowered to OR, odds ratio; CI, confidence interval. Unadjusted and adjusted OR for cases vs controls. In the multivariate model, we adjusted for sex, age and contraceptive use. *Eight subjects had more than one malignancy. Three subjects (one case and two controls) had a solid and hematological cancer, and were categorized in the group of the last diagnosed type of cancer. †In women only. In the multivariate model, we adjusted for age and contraceptive use. calculate the risk in subgroups. For instance, the point estimates in subjects with a history of hematological cancer more than 1 year ago suggest these patients may have a higher risk of CVT, but the width of the confidence interval precludes us from drawing any conclusions. Strengths of the study are the large number of patients with CVT, completeness of the data and the availability of an appropriate control population.
As with any case-control study, we cannot directly calculate the absolute risk of CVT in patients with cancer from our data. However, given the rarity of CVT, we can assume that the absolute risk of CVT is modest, possibly with the exception of ALL [18] . Nevertheless, clinicians should be suspicious of CVT when a patient who was recently diagnosed with cancer develops symptoms such as severe headache, focal neurological deficits and seizures [23] .
In conclusion, we have performed the first controlled study examining the association between cancer and CVT. Despite the fact that CVT is a rare disease, we were able to include a large number of patients by combining data from three large academic hospitals with expertise in CVT. Our data clearly indicate that cancer is a strong risk factor for CVT, especially in the first year of diagnosis and in patients with a hematological type of cancer. Addendum J. M. Coutinho designed the research, analyzed data, interpreted data, and co-wrote the paper; S. M. Silvis performed data collection, analyzed data, and co-wrote the paper; S. Hiltunen, E. Lindgren, K. Jood, and S. M. Zuurbier performed data collection and co-wrote the paper; S. Middeldorp, J. Putaala, S. C. Cannegieter, and T. Tatlisumak designed the research, interpreted data, and co-wrote the paper. All authors approved the final version.
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